Kinetics and metabolite profile of insulin glargine (Lantus®)

被引：0
|
作者：
Kuerzel, GU [1 ]
Sandow, J [1 ]
Seipke, G [1 ]
Lang, AM [1 ]
Mass, J [1 ]
Skrzipczyk, HJ [1 ]
机构：
[1] Aventis Pharma, Frankfurt, Germany
来源：
DIABETOLOGIA | 2001年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798
引用
收藏
页码：A208 / A208
页数：1
相关论文
共 50 条
  • [31] Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM or T2DM
    Deeg, Mark
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Zielonka, Jason
    Prince, Melvin J.
    Konrad, Robert J.
    DIABETES, 2014, 63 : A19 - A19
  • [32] Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus®) compared to bedtime NPH insulin in patients with type 2 diabetes
    Fonseca, V
    Bell, D
    Mecca, T
    DIABETES, 2001, 50 : A112 - A112
  • [33] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study
    Rosenstock, Julio
    Hollander, Priscilla
    Bhargava, Anuj
    Ilag, Liza
    Pollom, Robyn K.
    Huster, William J.
    Prince, Melvin J.
    DIABETES, 2014, 63 : A17 - A17
  • [34] Six Months Comparative Evaluation of Efficacy and Safety of Wockhardt's Biosimilar Insulin Glargine (Glaritus®) with Reference Insulin Glargine (Lantus®) in Type 2 Diabetes Mellitus in India
    Sharma, Surendra
    Ajmani, Ajay Kumar
    Khosla, Pooja
    Mukhopadhayay, Pradip
    Bhatia, Girish
    Kg, Prakash
    Chhaya, Gaurav
    Supe, Pravin
    Pavithran, Vinodkumar
    Bora, Hrishikesh
    Shah, Agam
    Ingole, Shahu Ashok
    Jain, Rishi
    DIABETES, 2019, 68
  • [35] Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
    Blevins, T. C.
    Dahl, D.
    Rosenstock, J.
    Ilag, L. L.
    Huster, W. J.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 726 - 733
  • [36] COMPARATIVE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LY2963016 INSULIN GLARGINE AND EU-AND US-APPROVED VERSIONS OF LANTUS® INSULIN GLARGINE IN HEALTHY SUBJECTS
    Linnebjerg, H.
    Lam, E. C. Q.
    Seger, M.
    Coutant, D.
    Chua, L. Y.
    Chong, C. L.
    Ferreira, M.
    Soon, D.
    Zhang, X.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S264 - S265
  • [37] Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus® Insulin Glargine in Healthy Subjects
    Linnebjerg, Helle
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Chong, Chew Lan
    Ferreira, Maria M.
    Soon, Danny
    Zhang, Xin
    DIABETES, 2014, 63 : A227 - A227
  • [38] Switch from continuous subcutaneous insulin infusion (CSII) with insulin lispro [Humalog®]to multiple daily injections (MDI) with insulin glargine (Lantus) and insulin lispro
    Bode, B
    Schleusener, D
    Strange, P
    DIABETES, 2003, 52 : A102 - A103
  • [39] Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial
    Home, Philip D.
    Lam, Raymond L. H.
    Carofano, Wendy L.
    Golm, Gregory T.
    Eldor, Roy
    Crutchlow, Michael F.
    Marcos, Michael C.
    Rosenstock, Julio
    Hollander, Priscilla A.
    Gallwitz, Baptist
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2220 - 2228
  • [40] The AT.LANTUS trial investigating treatment algorithms for insulin glargine therapy: results of the Type 1 study
    Gomis, R
    Storms, F
    Rodriguez, J
    Bianchi-Biscay, M
    Davies, M
    DIABETOLOGIA, 2004, 47 : A328 - A328
12345